4.7 Article

In vivo correction of murine hereditary tyrosinemia type I by φC31 integrase-mediated gene delivery

期刊

MOLECULAR THERAPY
卷 11, 期 3, 页码 399-408

出版社

CELL PRESS
DOI: 10.1016/j.ymthe.2004.11.001

关键词

nonviral somatic gene therapy; phage integrase; genetic disease

资金

  1. NHLBI NIH HHS [HL68112] Funding Source: Medline
  2. NIDDK NIH HHS [DK048252] Funding Source: Medline

向作者/读者索取更多资源

Phage phi C31 integrase is a site-specific recombinase that mediates efficient integration of circular extrachromosomal DNA into the host genome. Here, the integrase system was used to transfer the fumarylacetoacetate hydrolase (FAH) gene into the liver of mice affected with hereditary tyrosinemia type 1. Approximately 3.6% of transfected hepatocytes experienced an integration event. The absolute frequency of integration was 1/1374. A higher proportion of integrase-transfected FAH(+) hepatocytes displayed abnormal morphology (bizarre nuclei, enlarged cells) on day 25 after gene transfer, compared to cells not receiving integrase. The increased frequency of these abnormal cells correlated with the amount of integrase plasmid administered, suggesting some form of integrase toxicity in Fah(-/-) livers. The abnormal hepatocyte appearance was transient and livers analyzed after longer selection (90 days) showed 60% repopulation with only normal healthy FAH(+) hepatocytes. A total of seven different integration sites (accounting for > 90% of integration) were identified. Serial transplantation of integrase-corrected hepatocytes to Fah(-/-) recipients was successful, suggesting long-term viability of corrected cells and persistent gene expression through many rounds of cell division. The stability of transgene expression, relatively high integration frequency, and significant site specificity that characterize the phi C31 integration system suggest that it may have utility in many gene therapy settings.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据